ATE544783T1 - Neutralisierende anti tlr4/md-2 antikörper und verfahren zu deren verwendung - Google Patents

Neutralisierende anti tlr4/md-2 antikörper und verfahren zu deren verwendung

Info

Publication number
ATE544783T1
ATE544783T1 AT04817634T AT04817634T ATE544783T1 AT E544783 T1 ATE544783 T1 AT E544783T1 AT 04817634 T AT04817634 T AT 04817634T AT 04817634 T AT04817634 T AT 04817634T AT E544783 T1 ATE544783 T1 AT E544783T1
Authority
AT
Austria
Prior art keywords
tlr4
antibodies
methods
monoclonal antibodies
chimeric proteins
Prior art date
Application number
AT04817634T
Other languages
English (en)
Inventor
Greg Elson
Original Assignee
Novimmune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novimmune Sa filed Critical Novimmune Sa
Application granted granted Critical
Publication of ATE544783T1 publication Critical patent/ATE544783T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
AT04817634T 2003-12-10 2004-12-10 Neutralisierende anti tlr4/md-2 antikörper und verfahren zu deren verwendung ATE544783T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US52896203P 2003-12-10 2003-12-10
US52881103P 2003-12-10 2003-12-10
US52881203P 2003-12-10 2003-12-10
PCT/IB2004/004433 WO2005065015A2 (en) 2003-12-10 2004-12-10 Neutralizing antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
ATE544783T1 true ATE544783T1 (de) 2012-02-15

Family

ID=34753681

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04817634T ATE544783T1 (de) 2003-12-10 2004-12-10 Neutralisierende anti tlr4/md-2 antikörper und verfahren zu deren verwendung

Country Status (10)

Country Link
EP (1) EP1711531B9 (de)
JP (1) JP4762152B2 (de)
AT (1) ATE544783T1 (de)
AU (1) AU2004311541B2 (de)
CA (1) CA2548990C (de)
DK (1) DK1711531T3 (de)
ES (1) ES2382039T3 (de)
PL (1) PL1711531T3 (de)
PT (1) PT1711531E (de)
WO (1) WO2005065015A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7674884B2 (en) 2003-12-10 2010-03-09 Novimmune S.A. Neutralizing antibodies and methods of use thereof
US7312320B2 (en) * 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
DK1830881T3 (da) * 2004-12-10 2010-09-20 Novimmune Sa Kombinationsterapier, som er målrettet mod multiple toll-like-receptorer og anvendelse deraf
JP2008538007A (ja) 2005-04-15 2008-10-02 ベクトン，ディッキンソン アンド カンパニー 敗血症の診断
GB0620705D0 (en) 2006-10-18 2006-11-29 Opsona Therapeutics Compounds for the modulation of toll-like receptor activity and assay methods for the identification of said compounds
CA2689680C (en) 2007-05-14 2017-11-07 Novimmune Sa Fc receptor-binding polypeptides with modified effector functions
WO2009123737A2 (en) 2008-04-03 2009-10-08 Becton, Dickinson And Company Advanced detection of sepsis
EP3539987A1 (de) 2011-01-10 2019-09-18 NovImmune S.A. Anti-tlr4-antikörper und verfahren zur verwendung davon
AU2013237929B2 (en) 2012-03-29 2017-09-14 Novimmune S.A. Anti-TLR4 antibodies and uses thereof
EP3060250A1 (de) 2013-10-22 2016-08-31 NovImmune SA Verfahren und zusammensetzungen zur diagnose und behandlung von erkrankungen bei patienten mit erhöhten tlr4-ligandwerten und anderen biomarkern
JP2017501995A (ja) 2013-12-06 2017-01-19 ノビミューン エスアー 抗ｔｌｒ４抗体およびその使用方法
CN106062193B (zh) 2014-02-28 2020-08-25 安斯泰来制药株式会社 与人tlr2及人tlr4结合的双特异性抗体
KR101745520B1 (ko) * 2015-05-29 2017-06-12 아주대학교산학협력단 신규한 tlr4 길항제
US20190315878A1 (en) * 2016-11-07 2019-10-17 Argos Therapeutics Inc. Bispecific antibodies that modulate tlr-4 signaling and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5233409A (en) 1992-02-25 1993-08-03 Schwab Karl W Color analysis of organic constituents in sedimentary rocks for thermal maturity

Also Published As

Publication number Publication date
EP1711531A2 (de) 2006-10-18
CA2548990C (en) 2014-09-23
PT1711531E (pt) 2012-04-18
WO2005065015A2 (en) 2005-07-21
JP4762152B2 (ja) 2011-08-31
CA2548990A1 (en) 2005-07-21
WO2005065015A3 (en) 2005-12-01
ES2382039T3 (es) 2012-06-04
AU2004311541B2 (en) 2011-06-30
PL1711531T3 (pl) 2012-07-31
AU2004311541A1 (en) 2005-07-21
DK1711531T3 (da) 2012-04-30
EP1711531B1 (de) 2012-02-08
EP1711531B9 (de) 2012-07-25
JP2007517503A (ja) 2007-07-05

Similar Documents

Publication Publication Date Title
WO2007110678A3 (en) Neutralizing antibodies and methods of use thereof
ATE544783T1 (de) Neutralisierende anti tlr4/md-2 antikörper und verfahren zu deren verwendung
UA94576C2 (ru) Выделенное антитело, которое связывается с igf-1r, композиция, которая его содержит, и способы, которые касаются антител
WO2010027488A3 (en) Monoclonal antibodies
TW200716182A (en) Antibodies directed to CD20 and uses thereof
RS80704A (en) ANTI- av?6.ANTIBODIES
TW200626614A (en) Human monoclonal antibodies to influenza M2 protein and methods of making and using same
WO2005080431A3 (en) Monoclonal antibodies that specifically bind to folate receptor alpha
DE60130538D1 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
SG155883A1 (en) Anti-cd3 antibodies and methods of use thereof
EA200701443A1 (ru) Синтетические домены иммуноглобулина, обладающие свойствами связывания и сконструированные в участках молекулы, отличных от гипервариабельных участков
WO2005066867A3 (en) Modulators of cell-surface receptors of the ig-class
NZ512553A (en) Human monoclonal antibodies to cytotoxic T lymphocyte antigen 4 (CTLA-4)
NZ602780A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
AR077594A1 (es) Anticuerpos completamente humanos para btla (atenuante de linfocitos b y t)
DE60333732D1 (de) Internalisierung von anti cd74 monoklonalen antikörpern und deren verwendungen
WO2006071441A3 (en) Antibodies directed to gpnmb and uses thereof
WO2003078600A3 (en) Human monoclonal antibodies to influenza m2 protein and methods of making and using same
DK1414858T3 (da) Kamelid-enkeltkæde-VHH-antistoffer, fremgangsmåde til fremstilling heraf i et pattedyr samt anvendelser heraf
DE602006021324D1 (de) Verfahren zur herstellung stabiler b-lymphozyten
TW200700081A (en) Anti-ctla-4 antibody compositions
WO2003060080A3 (en) Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
WO2006113643A3 (en) High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies
TW200741000A (en) Method of producing lymphocytes
BRPI0413119A (pt) uso de anticorpos com adcc otimizada para tratar pacientes debilitados